Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Michael A. Robbins"'
Publikováno v:
BMC Public Health, Vol 16, Iss 1, Pp 1-9 (2016)
Abstract Background Both depression and the metabolic syndrome (MetS) are two major public health issues. The aim of this study was to examine associations between depressive symptoms, the use of antidepressant medications, and the prevalence of MetS
Externí odkaz:
https://doaj.org/article/3937d181bedf4791849af55b434b2409
Autor:
Michael C. Robbins
Publikováno v:
Journal of Ethnobiology. 43:12-18
Several ethnobiological studies have used the Jaccard Index, a qualitative, binary measure, to compare group similarities and differences in lists of plant and animal species, medicinals, foods, cultural utilities, and so on. We extend this effort by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f39e13ddb4a0582a8cae32cd8ccd1cd2
https://doi.org/10.1177/02780771231162195
https://doi.org/10.1177/02780771231162195
Autor:
Michael W. Robbins, Steven Davenport
Publikováno v:
Journal of Statistical Software, Vol 97, Iss 1 (2021)
The R package microsynth has been developed for implementation of the synthetic control methodology for comparative case studies involving micro- or meso-level data. The methodology implemented within microsynth is designed to assess the efficacy of
Externí odkaz:
https://doaj.org/article/257f27767c0d42c786cb6ecabda1326b
Autor:
Natalie A. Bezman, Amy Jhatakia, Alper Y. Kearney, Ty Brender, Mark Maurer, Karla Henning, Misty R. Jenkins, Amy J. Rogers, Paul J. Neeson, Alan J. Korman, Michael D. Robbins, Robert F. Graziano
Publikováno v:
Blood Advances, Vol 1, Iss 12, Pp 753-765 (2017)
Abstract: Elotuzumab, a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7) on myeloma cells, was developed to treat patients with multiple myeloma (MM). Elotuzumab has a dual mechanism of action that
Externí odkaz:
https://doaj.org/article/b48d5441929d44dabeefb1b6238bb93b
Autor:
Kerry S. Campbell, Adam D. Cohen, Michael D. Robbins, Natalie A. Bezman, Robert F. Graziano, Alper Y. Kearney, Amy Jhatakia, Andrew Gale, Yibin Yang, Kimberly B. Colby, Ashley M. James, Tatiana Pazina
Elotuzumab (Elo) is an IgG1 monoclonal antibody targeting SLAMF7 (CS1, CRACC, and CD319), which is highly expressed on multiple myeloma (MM) cells, natural killer (NK) cells, and subsets of other leukocytes. By engaging with FcγRIIIA (CD16), Elo pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dfd4fed3099da2d18527a6c9fd1f00e
https://doi.org/10.1158/2326-6066.c.6549927.v1
https://doi.org/10.1158/2326-6066.c.6549927.v1
Autor:
Kerry S. Campbell, Adam D. Cohen, Michael D. Robbins, Natalie A. Bezman, Robert F. Graziano, Alper Y. Kearney, Amy Jhatakia, Andrew Gale, Yibin Yang, Kimberly B. Colby, Ashley M. James, Tatiana Pazina
Supplementary Figures 1-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c1c3d238ebeff235065d4da790ca40
https://doi.org/10.1158/2326-6066.22542438.v1
https://doi.org/10.1158/2326-6066.22542438.v1
Autor:
Irene M. Ghobrial, Jamil Azzi, Michael D. Robbins, Yu-Tzu Tai, Daisy Huynh, Antonio Sacco, Chia-Jen Liu, Alexandre Detappe, Aldo Roccaro, Yuji Mishima, Michele Moschetta, Salomon Manier, Jennifer L. Guerriero, Amy Jhatakia, Natalie A. Bezman, Siobhan V. Glavey, Ahmed T. Kurdi
Supplementary Figure 1. In-vivo mouse model's schema; Supplementary Figure 2. Total BLI Flux of SCID.beige myeloma xenograft model and Kaplan-Meier survival analysis of the NSG xenograft model; Supplementary Figure 3. Elotuzumab does not affect myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b816a97b9fef9eac8cec3db8a996da
https://doi.org/10.1158/1535-7163.22505803
https://doi.org/10.1158/1535-7163.22505803
Autor:
Irene M. Ghobrial, Jamil Azzi, Michael D. Robbins, Yu-Tzu Tai, Daisy Huynh, Antonio Sacco, Chia-Jen Liu, Alexandre Detappe, Aldo Roccaro, Yuji Mishima, Michele Moschetta, Salomon Manier, Jennifer L. Guerriero, Amy Jhatakia, Natalie A. Bezman, Siobhan V. Glavey, Ahmed T. Kurdi
Elotuzumab, a recently approved antibody for the treatment of multiple myeloma, has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity by natural killer (NK) cells toward myeloma cells. The modulatory effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d170a9010f2820977fff9f1159ce1812
https://doi.org/10.1158/1535-7163.c.6538189.v1
https://doi.org/10.1158/1535-7163.c.6538189.v1
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This file contains the legends for the supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403647a09b3635dce22c4f3b8c519b1a
https://doi.org/10.1158/1078-0432.22473741
https://doi.org/10.1158/1078-0432.22473741
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
Purpose:Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12.Patients and Methods:This phase Ib/II study aimed to determine the safety and tolerability of ulocupluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d7c946d4f8b2b3fdf89b50a1279664
https://doi.org/10.1158/1078-0432.c.6528591
https://doi.org/10.1158/1078-0432.c.6528591